Featured Articles

  1. Companies To Watch: Aurion Biotech 8/30/2024

    Aurion Biotech is developing what could become the first allogeneic combination cell therapy for the treatment of corneal endothelial diseases.

  2. A Vision For Inclusion: Designing Trials That Benefit Visually Impaired Patients 8/30/2024

    Ocugen CMO Huma Qamar, MD, MPH, CMI contends that whether targeting vision-related conditions or other medical needs, sponsors must design trials that ensure vision-impaired patients are included.

  3. Google Life Sciences Leader Talks AI Opportunities And 'Watch Outs' For Biopharma 8/29/2024

    Shweta Maniar, Google’s global market leader for life sciences, spoke with Life Science Leader about how large and small biopharmaceutical companies are using AI to lower costs and expedite timelines.

  4. 'Doers, not Leaders': How Women Can Overcome A Common Workplace Struggle 8/20/2024

    Three key strategies can help women working in the biopharmaceutical industry shift from being seen as 'doers' to being recognized as 'leaders': vision, networking, and self-advocacy, writes Mary Beth Sandin.

  5. This Takeda Official Thinks Pharma 4.0 Won't Be Optional Much Longer 8/14/2024

    Advanced technology like automation was once seen only as a competitive advantage. That viewpoint is shifting amid greater reliance on digital technology.

  6. Mid-Year M&A Outlook: Challenges And Opportunities Update 8/8/2024

    In his mid-year 2024 M&A update, consultant David Stuart describes an uptick in deal activity, as well as collaborative and innovative approaches for early-stage biotech companies to overcome current capital market challenges, including fluctuating interest rates and persistent inflation.

  7. Where Are They Now? Caribou Biosciences 8/5/2024

    Caribou Biosciences is gunning for a Phase 3 pivotal trial start in 2025 for lead candidate CB-010, after cutting its CAR-NK preclinical activities to focus exclusively on developing CB-010 and two additional allogeneic CAR-T therapies.

  8. GLP-1 Drugs Driving Big Budget Impact: PwC's Medical Cost Trend 2025 8/1/2024

    PwC's Medical Cost Trend: Behind The Numbers 2025 report offers details on the key 'inflators' and 'deflators' impacting medical spending next year. The key inflator? You guessed it, weight loss drugs.

  9. An Updated View Of The Federal Segment: Veterans Affairs Formulary Management 7/24/2024

    As the largest integrated healthcare provider in the U.S., the VA presents tremendous opportunity for life sciences companies. This article provides actionable information about the VA's drug benefit design, drug pricing, clinical guidance, and formulary placement and management.

  10. COVID-19 Is Back: Are We "FLiRT"-ing With Another Disaster? 7/22/2024

    A combination of vaccine hesitancy and the emergence of new COVID-19 virus strains is prolonging health risks, particularly for older individuals and patients with underlying medical conditions. Vaccine developers must remain committed to updating vaccines and producing better treatments.